- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.05. | Amgen researchers confirm the lackluster data on the KRAS G12C drug AMG 510 reported at ESMO - but they still have a long way to go exploring options | ||
| 13.05. | Sanofi walks back Paul Hudson's promise of early vaccine access for the US - sort of | ||
| 13.05. | Merck pours $400M into flea drugs for Fido; Avrobio shows durability; Rhythm gets priority review | ||
| 13.05. | One year on, Capricor's stem cell therapy appears to help DMD patients in small study, but investors balk at the data | ||
| 13.05. | Boehringer Ingelheim sharpens retinal strategy, scooping up dry AMD drug from a Swiss team behind Novartis' Beovu | ||
| 13.05. | Sanofi flashes more PhIII data on new multiple myeloma drug, setting up battle with Darzalex | ||
| 13.05. | UPDATED: FDA spurns an application from Bristol Myers and bluebird for ide-cel, threatening to kill a $9 CVR | ||
| 13.05. | (Another) activist attack on Alexion, as Paul Singer-founded hedge fund calls for biotech to sell itself | ||
| 13.05. | The new CEO at troubled AMAG begins his battle against an array of threats by axing staff and slashing costs | ||
| 13.05. | Covid-19 roundup: Gilead selects 5 manufacturing partners for remdesivir; CanSino outlines PhI/II study in Canada | ||
| 13.05. | Precision therapy approach secures small biotech $42M haul to combat disease that inspired the Ice Bucket Challenge | ||
| 13.05. | FDA issues two guidances to accelerate Covid-19 treatments | ||
| 12.05. | Chinese biotech aims $232M in IPO cash to push next-gen prostate cancer drug; Immunomedics raises nearly a half-billion off approval | ||
| 12.05. | Positive pivotal cell graft data bring Novartis-backed Boston biotech step closer to finish line | ||
| 12.05. | With money flowing, Pliant Therapeutics heads to public well | ||
| 12.05. | Merck doubles down on Skyhawk's tech to drug RNA, promising $600M per autoimmune, metabolic target | ||
| 12.05. | Vivek Ramaswamy's brother, Shankar, spins out on his own, launching audacious gene therapy play | ||
| 12.05. | Covid-19 roundup: Aimmune pauses launch of peanut allergy therapy; India kicks off first coronavirus trial - its drug of choice is Fujifilm's favipiravir | ||
| 12.05. | Ex-DARPA chief Regina Dugan, Illumina founder Jay Flatley join Wellcome Trust fund to tackle global health's Sputnik moment | ||
| 11.05. | Genfit's NASH drug fails a closely-watched PhIII showdown, adding one more setback to a plagued field | ||
| 11.05. | CEPI bets $384M on Novavax's Covid-19 vaccine - covering R&D and manufacturing in the groundbreaking race to beat the pandemic | ||
| 11.05. | Merck to move global headquarters, returning to an old home | ||
| 11.05. | Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms | ||
| 11.05. | 'We're good to go': MyoKardia clinches crucial PhIII win, boosting genetic approach to cardio R&D | ||
| 11.05. | Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
